DIRECT ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH END STAGE KIDNEY DISEASE WITH ACUTE HCV INFECTION

DIRECT ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH END STAGE KIDNEY DISEASE WITH ACUTE HCV INFECTION

Background: Hepatitis C virus (HCV) infection is a public health problem. Such an infection is prevalent and aggressive in patients with end-stage kidney disease (ESKD). The efficacy and the safety of direct acting antivirus (DAA) in patients with acute HCV and ESKD is under investigation. The aim...

Full description

Bibliographic Details
Main Authors:	Nawfal R Hussein, Zana Saleem, Kais Abd
Format:	Article
Language:	English
Published:	PAGEPress Publications 2019-04-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/3922

Similar Items

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
by: Calogero Armando, et al.
Published: (2019-01-01)

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
by: Ezequiel Ridruejo, et al.
Published: (2020-01-01)

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
by: Ezequiel Ridruejo, et al.
Published: (2020-01-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
by: Armando Calogero, et al.
Published: (2019-01-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
by: Monica Basso, et al.
Published: (2021-04-01)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020-10-01)

Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy
by: Roberto Ravasio, et al.
Published: (2020-12-01)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
by: Dash S, et al.
Published: (2020-04-01)

Changes in tryptophan and phenylalanine in chronic HCV patients treated with direct acting antiviral (sofosbuvir)
by: Eman G. Behiry, et al.
Published: (2018-11-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
by: Óscar Brochado-Kith, et al.
Published: (2021-08-01)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
by: Cátia Dias, et al.
Published: (2018-01-01)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
by: Grenda Leite Pereira, et al.
Published: (2019-01-01)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
by: Nicola Imperatore, et al.
Published: (2017-11-01)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
by: Fabrizio Fabrizi, et al.
Published: (2019-10-01)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
by: Dimas Alexandre Kliemann, et al.
Published: (2016-01-01)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
by: Sonia Vibhakar Patel, et al.
Published: (2020-01-01)

Improvement in Waldenström’s Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals
by: Mattia Crespi, et al.
Published: (2018-11-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
by: Claudia Mascia, et al.
Published: (2017-01-01)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
by: Victor Virlogeux, et al.
Published: (2017-12-01)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
by: Claudia Minosse, et al.
Published: (2021-06-01)

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection
by: Stephan R. Marticorena Garcia, et al.
Published: (2021-02-01)

Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
by: Apichaya Khlaiphuengsin, et al.
Published: (2020-01-01)

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals
by: Zuzana Macek Jílková, et al.
Published: (2020-12-01)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals <sup>†</sup>
by: Silvia Molina-Carrión, et al.
Published: (2020-07-01)

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection
by: Leigh P. Johnson, et al.
Published: (2020-04-01)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
by: Chih-Chin Kao, et al.
Published: (2018-09-01)

Evaluation of direct-acting antivirals and antiretroviral therapy for HIV-HCV coinfected patients in the United States
by: Rivera, Josef Kyle Concepcion
Published: (2021)

LONG TERM FOLLOW UP AFTER HCV CURE WITH DIRECT ACTING ANTIVIRALS – REVIEW OF THE LITERATURE
by: Andreea Ruxandra Cazan, et al.
Published: (2018-12-01)

Correlation between platelet count and outcome of chronic HCV patients treated with direct-acting antivirals
by: Hosam M. Mohamed, et al.
Published: (2019-01-01)

Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans
by: Kendall R. Beck, et al.
Published: (2018-05-01)

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism
by: Lukashyk S.P., et al.
Published: (2020-03-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2021-12-01)

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
by: Haruka Uemura, et al.
Published: (2017-01-01)

Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease
by: Agatha Vranjkovic, et al.
Published: (2019-08-01)